Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that
NASDAQ OMX Group, Inc. (NASDAQ: NDAQ) will include the company in the
NASDAQ Biotechnology Index® (NASDAQ: NBI) effective prior to
market open on Monday, May 20, 2013.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on The NASDAQ Stock Market that are classified
as either biotechnology or pharmaceutical according to the Industry
Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a
modified market capitalization weighted index. Among the various
criteria that must be met in order to be eligible for inclusion in this
index are a market capitalization of at least $200 million and an
average daily trading volume of at least 100,000 shares. The NASDAQ
Biotechnology Index is re-ranked semi-annually in May and November.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused
on innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of
prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D.,
Sucampo's Chairman, Chief Executive Officer, Chief Scientific Officer,
and co-founder. Prostones, naturally occurring fatty acid metabolites
that have emerged as promising compounds with unique physiological
activities, can be targeted for the treatment of unmet or underserved
medical needs. For more information, please visit www.sucampo.com.
AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and
the tagline, The Science of Innovation, are registered trademarks of
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718